Sema4 (SMFR) Scheduled to Post Earnings on Thursday

Sema4 (NASDAQ:SMFRGet Rating) is scheduled to announce its earnings results after the market closes on Thursday, May 12th. Analysts expect the company to announce earnings of ($0.28) per share for the quarter. Sema4 has set its FY 2022 guidance at EPS.Persons that wish to listen to the company’s earnings conference call can do so using this link.

Sema4 (NASDAQ:SMFRGet Rating) last announced its earnings results on Monday, March 14th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.22) by $0.05. The firm had revenue of $57.80 million during the quarter, compared to analyst estimates of $50.90 million. On average, analysts expect Sema4 to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Shares of SMFR opened at $2.44 on Thursday. The company has a quick ratio of 4.44, a current ratio of 4.77 and a debt-to-equity ratio of 0.08. Sema4 has a twelve month low of $2.10 and a twelve month high of $15.21. The company has a 50 day moving average of $2.78 and a 200-day moving average of $4.39.

In other news, CFO Isaac Ro sold 21,735 shares of the stock in a transaction dated Thursday, February 10th. The shares were sold at an average price of $3.60, for a total value of $78,246.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Keith A. Meister bought 11,437,500 shares of Sema4 stock in a transaction that occurred on Friday, April 29th. The shares were bought at an average cost of $4.00 per share, with a total value of $45,750,000.00. Following the acquisition, the director now directly owns 26,931,250 shares in the company, valued at approximately $107,725,000. The disclosure for this purchase can be found here. Insiders sold 35,838 shares of company stock valued at $117,196 over the last three months.

Large investors have recently modified their holdings of the company. Goldman Sachs Group Inc. increased its stake in shares of Sema4 by 516.3% during the fourth quarter. Goldman Sachs Group Inc. now owns 93,369 shares of the company’s stock worth $416,000 after purchasing an additional 78,219 shares during the period. California State Teachers Retirement System acquired a new stake in shares of Sema4 during the fourth quarter worth $407,000. Bank of New York Mellon Corp bought a new stake in shares of Sema4 in the third quarter valued at about $374,000. Credit Suisse AG acquired a new position in shares of Sema4 in the fourth quarter valued at about $287,000. Finally, Legal & General Group Plc bought a new position in Sema4 during the fourth quarter worth about $249,000.

A number of research analysts recently weighed in on the stock. BTIG Research reaffirmed a “buy” rating and issued a $8.00 target price on shares of Sema4 in a research report on Friday, January 21st. Zacks Investment Research upgraded Sema4 from a “sell” rating to a “hold” rating in a report on Wednesday. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, Sema4 presently has an average rating of “Buy” and an average target price of $11.50.

About Sema4 (Get Rating)

Sema4 Holdings Corp., doing business as Sema4, operates as a health information company that enhances diagnosis, treatment, and prevention of disease through data. The company provides Centrellis, an AI-driven health intelligence platform that delivers comprehensive insights to biopharma to accelerate the drug discovery, development, and commercialization life-cycle, as well as analytics for actionable insights, pre-clinical and clinical trial support, and advanced sequencing services.

Featured Stories

Receive News & Ratings for Sema4 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sema4 and related companies with's FREE daily email newsletter.